11
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales:  
USA, Europe & Japan (2012-2014)
part 1 of 2
Key prescription drug sales jumped 4.9% in 2014, driven by an 
8.9% surge in USA sales; Europe returned to growth at 2.4%; 
Japan slumped 2.6% in yen.
EvaluatePharma
®
finds that collective sales from the developed 
markets of US, Europe and Japan for the Top 20 companies jumped 
4.9%, based on local currency growth. The USA market led the surge 
with sales from the Top 20 companies growing 8.9%, to $224.9bn. 
Europe appears to have turned the corner with local currency growth 
back in positive territory at 2.4%. Japan was the worst performing 
major market, declining 2.6% in 2014; add in a continuing yen 
depreciation and the translated US dollar value decline was 10%. 
Japan had its biennial reimbursed price cuts in April 2014, which saw 
prices cut by an average of 4.2%.
Rx Sales Growth
-2%
-4%
2%
4%
6%
8%
10%
2012/13
2013/14
USA
+2.9%
+8.9%
Europe
-0.8%
+2.4%
Japan
+1.7%
-2.6%
Subtotal – Top 20 Companies
+1.5%
+4.9%
0%
Source: EvaluatePharma® 22 May 2015
2013 & 2014 Regional Local Currency Rx Drug Sales Growth: 
Top 20 Companies in each Region
Growth
Sales ($bn)
(US$)
(Local Currency)
Region
2012
2013
2014
2012/13
2013/14
2012/13
2013/14)
USA
200.7
206.5
224.9
+2.9%
+8.9%
+2.9%
+8.9%
Europe 
124.3
127.4
130.4
+2.5%
+2.4%
-0.8%
+2.4%
Japan
78.2
65.5
58.6
-16.2%
-10.6%
+1.7%
-2.6%
Subtotal - Top 20 Companies
403.2
399.4
413.9
-0.9%
+3.6%
+1.5%
+4.9%
Unallocated
312.8
323.6
329.2
Total Worldwide Rx Sales
716.0
723.0
743.1
+1.0%
+2.8%
Regional Prescription Drug Sales (2012-2014):  
Observed Top 20 Companies in each Market
Source: EvaluatePharma
®
22 May 2015
EvaluatePharma
®
World Preview 2015
Pdf reorder pages online - re-order PDF pages in C#.net, ASP.NET, MVC, Ajax, WinForms, WPF
Support Customizing Page Order of PDF Document in C# Project
move pages in pdf; how to move pages in a pdf file
Pdf reorder pages online - VB.NET PDF Page Move Library: re-order PDF pages in vb.net, ASP.NET, MVC, Ajax, WinForms, WPF
Sort PDF Document Pages Using VB.NET Demo Code
how to change page order in pdf acrobat; how to reorder pages in pdf
12
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales: USA, Europe & Japan (2012-2014)
part 2 of 2
2%
Rx Drug Sales Growth
1%
3%
4%
5%
6%
7%
8%
2012/13
2013/14
USA (Private & Public)
+3%
+7.2%
Europe (Top 5)
+2.1%
Japan
+5.9%
Subtotal (USA+EU5+Japan)
+3.3%
Source: EvaluatePharma® 22 May 2015
2013 Regional Local Currency Growth Based on Government Data
0%
Country Drug Expenditures 2012 - 14 
Growth
Sales ($bn)
(US$)
(Local Currency)
Country
2012
2013
2014
2012/13
2013/14
2012/13
2013/14)
USA (Private & Public)
263.3
271.1
290.7
+3.0%
+7.2%
+3.0%
+7.2%
Europe (Top 5) – Germany, France, UK, Italy & Spain.
134.8
141.0
n/a
+4.6%
n/a
+2.1%
n/a
Japan
84.1
84.8
n/a
+0.7%
n/a
+5.9%
n/a
Sub-Total (USA+EU5+Japan)
482.2
496.9
n/a
+3.0%
n/a
+3.3%
n/a
Other
233.8
226.1
Total Worldwide Rx Sales
716.0
723.0
743.1
+1.0%
+2.8%
Reported Government Data for Prescription Drug Sales 
in USA, EU (Top 5 Countries) & Japan (2012-2014)
Source: EvaluatePharma® 22 May 2015
Currency Sensitivity Analysis
Source: EvaluatePharma® 22 May 2015
Currency (ending December)
2012
2013
2014
2015
2012/13
2013/14
2014/15
Euro (1€ = US $)
1.29
1.33
1.33
1.12
+3.3%
+0.0%
-16.1%
Japan (100 ¥ = US $)
1.25
1.03
0.95
0.84
-18.1%
-7.7%
-11.6%
China (1 RMB = US $)
0.16
0.16
0.16
0.16
+2.6%
-0.2%
-1.0%
Analysis is based on observing the reported geographic sales from US, Europe and Japan for the top 20 companies in each market in 2014. 
In addition, available reported government data on pharmaceutical purchases was reviewed.
EvaluatePharma
®
World Preview 2015
C# TIFF: How to Reorder, Rearrange & Sort TIFF Pages Using C# Code
Reorder, Rearrange and Sort TIFF Document Pages in C#.NET Application. C# TIFF Page Sorting Overview. Reorder TIFF Pages in C#.NET Application.
pdf move pages; pdf rearrange pages online
VB.NET PowerPoint: Sort and Reorder PowerPoint Slides by Using VB.
Sort and Reorder PowerPoint Slides Range with VB amount of robust PPT slides/pages editing methods powerful & profession imaging controls, PDF document, image
pdf reorder pages online; how to reorder pages in pdf online
13
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales:  
USA (2012-2014)
USA prescription drug market surged to 8.9% growth; Gilead 
stormed into number one spot in USA.
EvaluatePharma
®
finds that the USA prescription drug market surged 
by 8.9%, between 2013 and 2014, based on prescription drug sales 
for the top 20 companies. Gilead stormed into the number one 
position, adding $11.5bn in sales to amass $18.2bn in sales in 2014. 
Pfizer, the 2013 number one dropped three positions to now be 
ranked fourth in the USA market.
US Rx Sales ($bn)
Growth (US$)
Rank
Company
2012
2013
2014
2012/13
2013/14
1.
Gilead Sciences
5.6
6.7
18.2
+19.7%
+171.6%
2.
Johnson & Johnson
12.4
13.9
17.4
+12.3%
+25.0%
3.
Roche
14.8
16.3
17.3
+10.2%
+6.2%
4.
Pfizer
19.7
18.6
17.2
-5.8%
-7.6%
5.
Novartis
15.3
15.2
15.2
-0.4%
-0.3%
6.
Amgen
12.8
14.0
14.7
+9.6%
+4.9%
7.
Merck & Co
17.0
14.9
14.2
-12.8%
-4.3%
8.
Sanofi
12.8
12.9
13.9
+0.1%
+8.4%
9.
AbbVie
10.4
10.2
10.8
-2.4%
+6.5%
10.
Actavis
8.8
9.8
10.8
+11.7%
+10.0%
11.
GlaxoSmithKline
11.1
11.3
10.8
+1.5%
-4.5%
12.
Teva Pharmaceutical
10.4
10.5
10.6
+0.2%
+1.7%
13.
AstraZeneca
10.6
9.7
10.1
-8.6%
+4.4%
14.
Eli Lilly
12.3
12.9
9.1
+4.7%
-29.1%
15.
Bristol-Myers Squibb
10.4
8.3
7.7
-19.9%
-7.2%
16.
Novo Nordisk
5.9
7.0
7.7
+17.6%
+10.6%
17.
Biogen
1.8
3.6
5.6
+99.6%
+55.5%
18.
Allergan
3.4
3.8
4.5
+13.6%
+17.7%
19.
Celgene
3.2
3.9
4.5
+21.9%
+16.1%
20.
Valeant Pharmaceuticals
1.9
3.2
4.5
+66.8%
+39.8%
Total
200.7
206.5
224.9
+2.9%
+8.9%
USA Prescription Drug Sales (2012-2014): Top 20 Companies 
(Pro-forma adjusted for M&A)
Source: EvaluatePharma® 22 May 2015
4
USA Drug Prescription Sales ($bn) 
2
6
8
10
12
14
16
18
Gilead
Sciences
18.2
Johnson &
Johnson
17.4
Roche
17.3
Pfizer
17.2
Novartis
15.2
Amgen
14.7
Merck & Co
14.2
Sanofi
13.9
AbbVie
10.8
Actavis
10.8
Source: EvaluatePharma® 22 May 2015
USA Prescription Drug Sales in 2014: Top 10 Companies
0
part 1 of 2
EvaluatePharma
®
World Preview 2015
Read PDF in Web Image Viewer| Online Tutorials
"This online guide content is Out Dated! Extract images from PDF documents; Add, reorder pages in PDF files; Save and print PDF as you wish;
change page order pdf preview; rearrange pdf pages reader
C# PDF: C# Code to Process PDF Document Page Using C#.NET PDF
C# PDF Page Processing: Sort PDF Pages - online C#.NET tutorial page for how to reorder, sort, reorganize or re-arrange PDF document files using C#.NET code.
how to move pages around in pdf file; how to rearrange pdf pages reader
14
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales: USA (2012-2014)
part 2 of 2
Sales ($bn)
Growth (US$)
Country
2012
2013
2014
2012/13
2013/14
USA1
263.3
271.1
290.7
+3.0%
+7.2%
Country Level Retail Expenditures on Prescription Drug Sales (2012-2014)
Source: EvaluatePharma® 22 May 2015
1: Source: USA CMS.
2014 is a CMS forecast.
Analysis is based on observing the reported geographical prescription drug sales in the US for the top 20 companies in 2014. In addition, 
available government data (CMS) on pharmaceutical purchases of drugs was reviewed.
EvaluatePharma
®
World Preview 2015
VB.NET TIFF: Modify TIFF File by Adding, Deleting & Sort TIFF
Users can use it to reorder TIFF pages in ''' &ltsummary> ''' Sort TIFF document pages in designed powerful & profession imaging controls, PDF document, image
how to rearrange pages in pdf document; reorder pages of pdf
C# PDF Page Rotate Library: rotate PDF page permanently in C#.net
Online C# class source codes enable the ability to rotate single NET, add new PDF page, delete certain PDF page, reorder existing PDF pages and split
reorder pages in a pdf; how to move pages in pdf acrobat
15
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales:  
Europe (2012-2014)
part 1 of 2
Sales in Europe rebounded to grow 2.4% in 2014; Novartis 
remained number one in Europe; Gilead entered Top 10 for  
the first time.
EvaluatePharma
®
finds that European drug sales, for the Top 20 
companies, rebounded to 2.4% growth in local currency, after 
recording a 0.8% decline in 2013. Novartis remained the biggest 
player in Europe with sales of $17.5bn in 2014. Gilead Sciences 
entered the top 10 for the first time, with sales growing 50% to  
reach €4.1bn in 2014.
4
European Drug Sales ($bn) 
2
6
8
10
12
14
16
18
Novartis
17.5
Sanofi
13.1
Pfizer
10.9
Roche
10.3
Merck & Co
9.6
GlaxoSmithKline
8.1
AstraZeneca
6.6
Bayer
5.8
Teva
Pharmaceutical
5.8
Gilead
Sciences
5.4
Source: EvaluatePharma® 22 May 2015
European Prescription Drug Sales in 2014: Top 10 Companies
0
EU Rx Sales ($bn)
Growth (US$)
EU Rx Sales (€bn)
Growth (€)
Rank
Company
2012
2013
2014
2012/13
2013/14
2012
2013
2014
2012/13
2013/14
1.
Novartis
16.0
17.2
17.5
+7.4%
+1.8%
12.4
12.9
13.2
+3.9%
+1.8%
2.
Sanofi
13.5
13.3
13.1
-1.7%
-1.1%
10.5
10.0
9.9
-4.9%
-1.1%
3.
Pfizer
11.8
11.0
10.9
-6.2%
-0.9%
9.2
8.3
8.2
-9.2%
-0.9%
4.
Roche
9.6
10.0
10.3
+4.6%
+3.2%
7.4
7.5
7.8
+1.2%
+3.2%
5.
Merck & Co
9.8
9.6
9.6
-1.3%
-0.4%
7.6
7.2
7.2
-4.5%
-0.4%
6.
GlaxoSmithKline
7.9
8.1
8.1
+2.1%
+0.1%
6.2
6.1
6.1
-1.2%
+0.1%
7.
AstraZeneca
7.1
6.7
6.6
-6.8%
-0.3%
5.6
5.0
5.0
-9.8%
-0.3%
8.
Bayer
4.7
5.2
5.8
+10.1%
+12.2%
3.7
3.9
4.4
+6.6%
+12.2%
9.
Teva Pharmaceutical
5.8
6.0
5.8
+3.3%
-2.8%
4.5
4.5
4.4
-0.0%
-2.8%
10.
Gilead Sciences
3.3
3.6
5.4
+8.4%
+50.6%
2.6
2.7
4.1
+4.9%
+50.6%
11.
Eli Lilly
4.3
4.3
4.5
+1.8%
+3.9%
3.3
3.3
3.4
-1.4%
+3.9%
12.
Menarini
4.1
4.4
4.4
+5.8%
+0.2%
3.2
3.3
3.3
+2.4%
+0.2%
13.
Amgen
3.6
3.9
4.3
+8.4%
+11.9%
2.8
2.9
3.2
+4.9%
+11.9%
14.
AbbVie
3.5
3.9
4.3
+9.8%
+10.7%
2.7
2.9
3.2
+6.3%
+10.7%
15.
Boehringer Ingelheim
3.6
3.9
3.6
+6.9%
-6.4%
2.8
2.9
2.7
+3.5%
-6.4%
16.
Bristol-Myers Squibb
3.7
3.9
3.6
+6.0%
-8.6%
2.9
3.0
2.7
+2.6%
-8.6%
17.
Novo Nordisk
3.4
3.6
3.6
+5.0%
+0.5%
2.6
2.7
2.7
+1.6%
+0.5%
18.
Merck KGaA
3.2
3.3
3.2
+2.5%
-2.3%
2.5
2.5
2.4
-0.8%
-2.3%
19.
Astellas Pharma
2.4
2.6
2.9
+11.1%
+8.5%
1.8
2.0
2.2
+7.5%
+8.5%
20.
Takeda
3.0
3.0
2.8
-0.4%
-6.9%
2.3
2.2
2.1
-3.6%
-6.9%
Total*
124.3
127.4
130.4
+2.5%
+2.4%
96.7
95.9
98.2
-0.8%
+2.4%
Currency Impact ($bn) at 2012 rates:
4.1
4.2
Europe Prescription Drug Sales (2012-2014): Top 20 Companies
Source: EvaluatePharma
®
22 May 2015
EvaluatePharma
®
World Preview 2015
Note: Johnson & Johnson does not disclose European pharmaceutical sales.
Menarini 2014 sales figure is an estimate of total revenue.
Novartis’s sales based on actual and estimated segment sales.
C# Word: How to Create Word Document Viewer in C#.NET Imaging
Offer mature Word file page manipulation functions (add, delete & reorder pages) in document viewer; (Directly see online document viewer demo here.).
rearrange pages in pdf file; how to move pages in pdf reader
VB.NET TIFF: VB.NET Sample Code to Process & Manage TIFF Page
certain TIFF page, and sort & reorder TIFF pages in Process TIFF Pages Independently in VB.NET Code. powerful & profession imaging controls, PDF document, image
change pdf page order online; move pages in pdf online
16
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales: Europe (2012-2014)
part 2 of 2
Gov Purchases ($bn)
Growth (US$)
Gov Purchases (€; £bn)
Growth (LC)
Country
2012
2013
2014
2012/13
2013/14
2012
2013
2014
2012/13
2013/14
Germany (€)
43.8
47.6
+8.5%
34.1
35.8
+5.0%
France (€)
35.0
35.6
+1.8%
27.2
26.8
-1.5%
Italy (€)
22.2
23.1
+4.2%
17.3
17.4
+0.9%
UK (England) (£)
21.2
22.5
+6.3%
13.4
14.4
+7.6%
Spain (€)
12.6
12.2
12.4
-2.9%
+1.9%
9.8
9.2
9.4
-6.0%
+1.9%
Top 5 EU Countries
134.8
141.0
+4.6%
+2.1%
Currency Impact ($bn) at 2012 rates:
3.5
Country Level Expenditures on Prescription Drugs (Government Disclosed)
Source: EvaluatePharma® 22 May 2015
Currency Rate
2012
2013
2014
2012/13
2013/14
1€ = US $
1.29
1.33
1.33
+3%
+0%
1£ = US $
1.58
1.56
1.65
-1%
+5%
Source: EvaluatePharma
®
22 May 2015
Analysis is based on observing the reported geographic sales for the top 20 companies in Europe in 2014. In addition, available reported 
government data on pharmaceutical purchases for 2012, 2013 and 2014 was reviewed.
EvaluatePharma
®
World Preview 2015
17
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales:  
Japan (2012-2014)
part 1 of 2
Japanese market contracted 10% in dollar-terms due to 
depreciation of the yen; Takeda remained number one.
EvaluatePharma
®
finds that Japanese prescription drug sales, in yen, 
declined 2.6% in 2014; however, due to the continuing depreciation 
of the yen, sales declined 10.6% when expressed in terms of US 
dollars. Japan had its biennial reimbursed price cuts in April 2014, 
which saw prices cut by an average of 4.2%. 
2
Japanese Drug Sales ($bn) 
1
3
4
5
6
Takeda
5.1
Astellas
Pharma
4.6
Pfizer
4.4
Daiichi
Sankyo
4.4
Roche
(Chugai)
3.6
Bayer
3.6
Merck & Co
3.4
Otsuka
Holdings
3.3
Mitsubishi
Tanabe
Pharma
3.0
Sanofi
2.8
Source: EvaluatePharma® 22 May 2015
Japanese Prescription Drug Sales in 2014: Top 10 Companies
0
Japan Rx Sales ($bn)
Growth (US$)
Japan Rx Sales (¥bn)
Growth (¥)
Rank
Company
2012
2013
2014
2012/13
2013/14
2012
2013
2014
2012/13
2013/14
1.
Takeda
7.1
5.8
5.1
-18.3%
-11.7%
591
582
564
-1.4%
-3.2%
2.
Astellas Pharma
6.7
5.3
4.6
-21.4%
-14.0%
560
531
501
-5.2%
-5.6%
3.
Pfizer
6.5
5.1
4.4
-21.6%
-13.6%
521
499
467
-4.2%
-6.4%
4.
Daiichi Sankyo
5.4
4.9
4.4
-9.2%
-9.6%
445
487
483
+9.5%
-0.8%
5.
Roche (Chugai)
4.4
3.7
3.6
-16.1%
-1.8%
350
358
381
+2.5%
+6.4%
6.
Bayer
3.1
3.3
3.6
+6.0%
+8.7%
247
319
376
+29.5%
+17.8%
7.
Merck & Co
5.0
3.9
3.4
-20.7%
-14.2%
397
385
358
-3.1%
-7.0%
8.
Otsuka Holdings
4.3
3.7
3.3
-12.5%
-11.2%
353
373
363
+5.6%
-2.6%
9.
Mitsubishi Tanabe Pharma
4.3
3.4
3.0
-20.9%
-13.2%
358
342
325
-4.6%
-4.8%
10.
Sanofi
4.2
3.3
2.8
-20.9%
-15.5%
336
325
297
-3.3%
-8.4%
11.
Novartis
4.0
3.3
2.7
-17.5%
-18.2%
319
322
285
+0.8%
-11.4%
12.
Eisai
3.7
3.1
2.5
-16.6%
-18.1%
309
311
280
+0.6%
-10.1%
13.
Kyowa Hakko Kirin
3.3
2.7
2.4
-17.6%
-11.0%
259
261
252
+0.6%
-3.5%
14.
GlaxoSmithKline
3.1
2.6
2.4
-16.9%
-8.3%
249
253
251
+1.6%
-0.6%
15.
AstraZeneca
2.9
2.5
2.2
-14.4%
-10.4%
232
242
235
+4.5%
-2.9%
16.
Eli Lilly
2.2
2.1
2.0
-8.1%
-1.8%
179
201
214
+12.3%
+6.4%
17.
Boehringer Ingelheim
2.3
2.0
1.9
-9.5%
-5.3%
180
199
204
+10.5%
+2.6%
18.
Shionogi
2.0
1.7
1.5
-16.2%
-12.2%
166
168
162
+1.1%
-3.7%
19.
Sumitomo Dainippon Pharma
2.1
1.7
1.4
-18.7%
-16.6%
175
172
157
-1.9%
-8.5%
20.
Meiji Holdings
1.6
1.4
1.3
-13.2%
-3.5%
133
139
147
+4.8%
+5.9%
Total
78.2
65.5
58.6
-16.2%
-10.6%
6,359
6,469
6,304
+1.7%
-2.6%
Currency Impact ($bn) at 2012 rates:
-12.4
-17.3
Japanese Prescription Drug Sales (2012-2014): Top 20 Companies
Source: EvaluatePharma
®
22 May 2015
EvaluatePharma
®
World Preview 2015
18
Copyright © 2015 Evaluate Ltd. All rights reserved.
Regional Prescription Drug Sales: Japan (2012-2014)
part 2 of 2
Gov Purchases ($bn)
Growth (US$)
Gov Purchases (¥bn)
Local % Growth
Country
2012
2013
2014
2012/13
2013/14
2012
2013
2014
2012/13
2013/14
Japan
84.1
84.8
+0.7%
6,643
7,038
+5.9%
Currency Rate (Ending 31 March)
2012
2013
2014
2015
May
Fiscal year
2011
2012
2013
2014
2015
2011/12
2012/13
2013/14
2014/15
1 ¥ = $
0.0127
0.0120
0.0100
0.0091
0.0083
-5%
-17%
-9%
-9%
1 $ = ¥
79.0
83.0
100.2
109.9
120.4
Government Purchases
Source: EvaluatePharma® 22 May 2015
NOV 2012: Yen depreciation due to change in monetary policy after Shinzo Abe elected Prime Minister.
Analysis is based on observing the reported geographical prescription drug sales in Japan for the top 20 companies in 2014. In addition, 
available government data on pharmaceutical purchases of drugs was reviewed.
EvaluatePharma
®
World Preview 2015
19
Copyright © 2015 Evaluate Ltd. All rights reserved.
Worldwide Prescription Drug Sales in 2020: 
Top 20 Companies
part 1 of 2
Novartis forecast to record highest worldwide sales of 
prescription drugs in 2020.
EvaluatePharma
®
finds that Novartis will remain the number one 
pharmaceutical company through to 2020 with total prescription 
drug sales of $53.3bn, representing a 5.4% share of the entire world 
market. Actavis’s prescription drug sales are forecast to almost triple 
between 2014 and 2020, primarily as a result of its acquisition of 
Allergan in March 2015, which is expected to add over $10.3bn to its 
2020 worldwide prescription drug sales, and of Forest Laboratories 
in July 2014. Celgene is forecast to make its debut in the top 20, 
rising nine places, by 2020 with its anti-cancer therapeutic Revlimid 
and its immunosuppressant Otezla adding a combined $6.6bn to its 
2020 prescription drug sales. Overall, global prescription drug sales 
are expected to grow, on average, 5% per year between 2014 and 
2020 and reaching almost one trillion dollars by 2020.
Source: EvaluatePharma
®
22 May 2015
Worldwide Prescription Drug Sales in 2020: Top 10 Companies
WW Prescription Drug Sales ($bn)
CAGR 2014 - 2020 (%)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
+20%
+18%
+14%
+16%
+12%
+10%
+8%
+2%
+4%
+6%
+0%
Novartis
53.3
+0
+2%
Sales ($bn)
Ranking Change 2014-20
Pfizer
44.9
+0
+0%
Roche
44.7
+0
+2%
Merck & Co
42.0
+1
+2%
Sanofi
+0%
38.9
-1
Johnson &
Johnson
32.7
+0
+1%
GlaxoSmithKline
31.4
+0
+1%
Actavis
28.4
+11
+17%
AstraZeneca
27.8
-1
+1%
Gilead
Sciences
26.9
-1
+2%
WW Rx Sales ($bn)
2020 Change
WW Market Share
Rank 
Rank
Company
2014
2020
CAGR
vs. Jun 14
2014
2020
Chg. (+/-)
Chg. (+/-)
1.
Novartis
46.1
53.3
+2%
-1.1
6.2%
5.4%
-0.8pp
+0
2.
Pfizer
44.5
44.9
+0%
-3.0
6.0%
4.5%
-1.4pp
+0
3.
Roche
40.1
44.7
+2%
-7.7
5.4%
4.5%
-0.9pp
+0
4.
Merck & Co
36.6
42.0
+2%
+2.5
4.9%
4.3%
-0.7pp
+1
5.
Sanofi
38.2
38.9
+0%
-11.1
5.1%
3.9%
-1.2pp
-1
6.
Johnson & Johnson
30.7
32.7
+1%
-3.2
4.1%
3.3%
-0.8pp
+0
7.
GlaxoSmithKline
30.3
31.4
+1%
-9.8
4.1%
3.2%
-0.9pp
+0
8.
Actavis
11.1
28.4
+17%
+18.0
1.5%
2.9%
+1.4pp
+11
9.
AstraZeneca
25.7
27.8
+1%
+1.9
3.5%
2.8%
-0.6pp
-1
10.
Gilead Sciences
24.5
26.9
+2%
+3.2
3.3%
2.7%
-0.6pp
-1
Worldwide Prescription Drug Sales (2014 - 2020): 
Top 20 Companies & Total Market
Source: EvaluatePharma® 22 May 2015
EvaluatePharma
®
World Preview 2015
Top 11-20 continued over…
WW Rx Sales ($bn)
2020 Change
WW Market Share
Rank 
Rank
Company
2014
2020
CAGR
vs. Jun 14
2014
2020
Chg. (+/-)
Chg. (+/-)
11.
AbbVie
19.9
26.0
+5%
+2.8
2.7%
2.6%
-0.0pp
-1
12.
Amgen
19.3
22.8
+3%
+1.9
2.6%
2.3%
-0.3pp
-1
13.
Novo Nordisk
15.8
22.6
+6%
-3.2
2.1%
2.3%
+0.2pp
+2
14.
Bristol-Myers Squibb
12.0
22.0
+11%
+0.4
1.6%
2.2%
+0.6pp
+4
15.
Eli Lilly
16.3
18.9
+2%
+0.9
2.2%
1.9%
-0.3pp
-2
16.
Bayer
16.3
18.0
+2%
-4.5
2.2%
1.8%
-0.4pp
-2
17.
Celgene
7.5
16.8
+14%
+4.5
1.0%
1.7%
+0.7pp
+9
18.
Teva Pharmaceutical
17.5
15.3
-2%
+0.1
2.4%
1.6%
-0.8pp
-6
19.
Boehringer Ingelheim
13.4
15.2
+2%
-0.4
1.8%
1.5%
-0.3pp
-3
20.
Takeda
13.0
14.9
+2%
-3.4
1.7%
1.5%
-0.2pp
-3
Total Top 20
478.9
563.4
+3%
64.4%
57.1%
-7.3pp
Other
264.2
423.4
+8%
35.6%
42.9%
Total
743.1
986.8
+5%
100.0%
100.0%
20
Copyright © 2015 Evaluate Ltd. All rights reserved.
Worldwide Prescription Drug Sales in 2020: Top 20 Companies
part 2 of 2
Source: EvaluatePharma
®
22 May 2015
Note: Prescription drug sales include generic drug sales. Excludes alliance revenue and royalties where possible.
EvaluatePharma
®
World Preview 2015
Documents you may be interested
Documents you may be interested